Early Evidence Showed THC Reduced Chemotherapy Nausea but Raised Safety Questions | Research

The takeaway

A critical review of clinical studies found THC showed antiemetic promise for cancer patients undergoing chemotherapy, but identified significant gaps in understanding its clinical pharmacology and safety profile.

Read this if you want to understand the early evidence base that eventually led to FDA-approved THC medications for nausea.

THC antiemetic research was among the most active areas of cannabinoid clinical research by 1981

What the researchers found

By 1981, both government and industry had invested substantial effort in isolating cannabis compounds with medical potential. THC's ability to reduce nausea and vomiting during cancer chemotherapy had emerged as one of the most active areas of investigation.

This review critically evaluated the clinical trial evidence for THC as an antiemetic, finding that while the drug showed efficacy, the evidence base had significant weaknesses. The reviewers identified deficiencies in understanding THC's basic clinical pharmacology, including absorption, metabolism, and dose-response relationships, that complicated evaluation of its safety and effectiveness.

Why it matters

This review came at a critical juncture when THC was being seriously considered as a prescription medication. Its identification of pharmacological knowledge gaps helped shape the research agenda that eventually led to FDA approval of dronabinol (synthetic THC) in 1985.

The numbers in context

The review covered six years of research activity (approximately 1975-1981) across both government and private sector investigations.

How the study worked

Critical review of published clinical studies evaluating delta-9-THC as an antiemetic in cancer chemotherapy patients. The review assessed both efficacy and safety data.

What this study cannot tell us

The review itself acknowledged that the evidence base had significant deficiencies. As a review from 1981, it predates decades of subsequent antiemetic research including modern serotonin antagonists that now dominate nausea management.

How to read the evidence

A critical review of clinical studies published in a pharmacy journal. Reviews synthesize existing evidence but are limited by the quality and quantity of available studies.

When this study was published

Published in 1981, four years before dronabinol received FDA approval. The antiemetic landscape has changed dramatically with newer drug classes.

The bigger picture

The trajectory from this 1981 review to dronabinol's 1985 FDA approval for chemotherapy-induced nausea shows how critical evaluation of early evidence can accelerate therapeutic development. Many of the pharmacological questions raised here were eventually addressed in the studies that supported approval.

Questions still open

How did the pharmacological gaps identified in this review get resolved in subsequent research? How does THC compare to modern antiemetics developed since 1981?

Common questions

Did THC work against chemotherapy nausea?

The evidence showed efficacy, but the reviewers noted significant gaps in understanding THC's pharmacology that complicated safety and dosing assessments.

Did this lead to an approved medication?

Yes. Dronabinol (synthetic THC) was approved by the FDA in 1985 for chemotherapy-induced nausea, partly building on the evidence base reviewed here.

Read the original research

A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol.

Drug intelligence & clinical pharmacy, 15(11), 867-75

View on PubMed ↗

Citation

Cocchetto, D M; Cook, L F; Cato, A E. (1981). A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol.. Drug intelligence & clinical pharmacy, 15(11), 867-75.